Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval

Executive Summary

FDA’s Nonprescription Drugs Advisory Committee will meet Sept. 4-5 to discuss the scope of safety testing necessary for OTC sunscreen ingredients, following FDA’s rejection this year of three time-and-extent applications to add new sunscreen actives to the OTC monograph. The committee’s input will be valuable if FDA faces deadlines for sunscreen TEA decisions under the Sunscreen Innovation Act, which passed the House July 29.

Advertisement

Related Content

Senators Optimistic As Sunscreen Bill Heads For HELP Committee Markup
FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda
Without User Fees, FDA’s Monograph Review Process Lacks Manpower
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA Questions Spray Sunscreen Safety, Efficacy & Monograph Status

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS019145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel